Insider Trading Activity Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) – Director Sold 10,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)

Robert J Kammer , Director of Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) reportedly Sold 10,000 shares of the company’s stock at an average price of 3.05 for a total transaction amount of $30,500.00 SEC Form

Insider Trading History For Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)

  • On 5/19/2015 Donald Paul Miloni, Major Shareholder, sold 410,000 with an average share price of $8.00 per share and the total transaction amounting to $3,280,000.00.View SEC Filing
  • On 6/30/2015 Opaleye Management Inc., Major Shareholder, bought 35,000 with an average share price of $7.90 per share and the total transaction amounting to $276,500.00.View SEC Filing
  • On 3/11/2016 Opaleye Management Inc., Major Shareholder, bought 45,000 with an average share price of $3.65 per share and the total transaction amounting to $164,250.00.View SEC Filing
  • On 12/19/2016 Richard L Md Lindstrom, Director, bought 100,000 with an average share price of $1.79 per share and the total transaction amounting to $179,000.00.View SEC Filing
  • On 12/19/2016 Mark L Baum, CEO, bought 156,000 with an average share price of $1.79 per share and the total transaction amounting to $279,240.00.View SEC Filing
  • On 12/19/2016 Andrew R Boll, CFO, bought 39,000 with an average share price of $1.79 per share and the total transaction amounting to $69,810.00.View SEC Filing
  • On 7/17/2017 Robert J Kammer, Director, sold 10,000 with an average share price of $3.05 per share and the total transaction amounting to $30,500.00.View SEC Filing

    • Analyst Ratings For Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)
    These are 2 Buy Ratings .
    The current consensus rating for Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) is Buy (Score: 3.00) with a consensus target price of $5.00 , a potential (68.92% upside)

    Analyst Ratings History For Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)

    • On 7/23/2015 Sterne Agee CRT Initiated Coverage of rating Buy with a price target of $10.00
    • On 11/28/2016 HC Wainwright Initiated Coverage of rating Buy with a price target of $5.00
    • On 3/22/2017 Rodman & Renshaw Reiterated Rating Buy with a price target of $5.00

    Recent Trading Activity for Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)
    Shares of Imprimis Pharmaceuticals, Inc. closed the previous trading session at 2.96 down -0.04 -1.33% with 155,347 shares trading hands.